File photograph of a vial labelled Sputnik V. (Reuters)
The Russian vaccine Sputnik V has shown an efficacy of 91.6 % and if accepted it volition beryllium India’s 3rd vaccine aft Covaxin and Covishield.
The Subject Expert Committee (SEC), constituted by the cardinal government, is apt to conscionable connected Wednesday connected drugmaker Dr Reddy’s exertion seeking exigency usage authorisation for the Sputnik V vaccine successful India. If the SEC gives a nod, Sputnik V volition beryllium India’s 3rd vaccine.
Dr Reddy’s has partnered with the Sputnik V vaccine to tally objective trials successful India and had submitted further information past week that was sought by the adept panel. The SEC had asked the drugmaker to taxable the immunogenicity information aft a gathering that was held connected February 24.
The Ministry of Health had appointed the SEC to conscionable implicit Dr Reddy’s exertion connected Wednesday. Dr Reddy’s has partnered with Russia Direct Investment Fund (RDIF) to bring the Sputnik V vaccine to India.
The Russian vaccine has shown an efficacy of 91.6 % and if accepted, Sputnik V volition beryllium India’s 3rd vaccine aft Covaxin and Covishield.
The vaccination thrust successful India had began connected January 16 with 2 vaccines that are location grown — Covaxin developed by Bharat Biotech and Oxford-AstraZeneca’s Covishield manufactured by the Serum Institute of India.
Both the vaccines were granted “conditional approval” from the DCGI connected January 3.